Exact Sciences Corporation EXAS is focused on further promoting Cologuard as the standard of care. The company prioritizes high-return pipeline opportunities with large patient impacts, which is ...

Exact Sciences Corporation EXAS is focused on further promoting Cologuard as the standard of care. The company prioritizes high-return pipeline opportunities with large patient impacts, which is ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company expects to report revenue of $713 million for the fourth quarter ...

EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection ...

Colonoscopies are considered the gold standard for detecting colorectal cancer. But some dread the idea of the invasive procedure and the prep required the day before you have it. The FDA last ...

Looking to revisit the MCU franchise now that 'What If...?' season three is here? Whether you want to watch all the films and series in order of release or in chronological story order, we've got ...

The report also indicates that while PAMA has cut spending on routine tests, overall lab spending has risen as genetic testing continues to grow.

IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news ...